Expression of tissue-type and urokinase-type plasminogen activator activities in chronic venous leg ulcers

Vasa - Journal of Vascular Diseases

Volumn 28, Issue 2, 1999, Pages 101-105

  Rogers, Alan A ^a   Burnett, S ^a   Lindholm, C ^b   Bjellerup, M ^c   Christensen, O B ^c   Zederfeldt, B ^c   Peschen, M ^d   Chen, W Y J ^a  

^a UK   (United Kingdom)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d ConvaTec WHRI ^*

Author keywords

Histological zymography; Pathophysiology; Proteinase; Urokinase; Venous leg ulcer

Indexed keywords

PROTEINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ADULT; AGED; ARTICLE; CHRONICITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; LEG ULCER; MALE; PATHOPHYSIOLOGY; PROTEIN EXPRESSION;

EID: 0033040373     PISSN: 03011526     EISSN: None     Source Type: Journal    
DOI: 10.1024/0301-1526.28.2.101     Document Type: Article

References (36)

1. Blasi F, Vassalli J-D, Danø K. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol 1987; 104: 801-4.
2. Bjellerup M, Lindholm C, Christensen OB, Zederfeldt B. Analysis of therapy-resistant venous leg ulcers. Can triple-layer treatment initiate healing? Wound Rep Regen 1993; 1: 54-62.
3. Bradbury AW, Murie JA, Ruckley CV. Role of the leucocyte in the pathogenesis of vascular disease. Br J Surg 1993; 80: 1503-12.
4. Brommer EJP, Dooijewaard G, Dijkmans BAC, Breedveld FC. Depression of tissue-type plasminogen activator and enhancement of urokinase-type plasminogen activator as an expression of local inflammation. Thromb Haemost 1992; 68: 180-4.
5. Chen WYJ, Rogers AA. Studies of growth factor and matrix proteinase activities during early stages of wound healing. In: Altmeyer P, El Gammal S, Hoffmann K, Hutchinson J (eds) Wound Healing and Skin Physiology, Berlin: Springer-Verlag 1995; 239-43.
6. Collen D. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy. J Cell Biochem 1987; 33: 77-86.
7. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139-266.
8. De Vries TJ, Quax PHA, Denijn M, Verrijp KN, Verheijen JH, Verspaget HW, Weidle UH, Ruiter DJ, van Muijen GNP. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol 1994; 144: 70-81.
9. Gold LI, Rostagno A, Frangione B, Passalaris T. Localization of the cleavage sites on fibronectin following digestion by urokinase. J Cell Biochem 1992; 50: 441-52.
10. Grøndahl-Hansen J, Lund LR, Ralfkiær E, Ottevanger V, Danø K. Urokinase- and tissue-type plasminogen activators in keratinocytes during wound reepithelialization in vivo. J Invest Dermatol 1988; 90: 790-5.
11. Grøndahl-Hansen J, Kirkeby LT, Ralfkiær E, Kristensen P, Lund LR, Danø K. Urokinase-type plasminogen activator in endothelial cells during acute inflammation of the appendix. Am J Pathol 1989; 135: 631-6.
12. Hahn J, Jünger M, Friedrich B, Zuder D, Steins A, Hahn M, Klyscz T. Cutaneous inflammation limited to the region of the ulcer in chronic venous insufficiency. VASA 1997; 26: 277-81.
13. Herrick S, Ashcroft G, Ireland G, Horan M, McCollum C, Ferguson MWJ. Up-regulation of elastase in acute wounds of healthy aged humans and chronic venous leg ulcers are associated with matrix degradation. Lab Invest 1997; 77: 281-8.
14. Hibino T, Takahashi T, Leuthardt D, Goetinck PF. Involvement of urokinase plasminogen activator (uPA) in keratinocyte proliferation. J Invest Dermatol 1994; 102: 641.
15. Jensen PJ, Lavker RM. Modulation of the plasminogen activator cascade during enhanced epidermal proliferation in vivo. Cell Growth Differ 1996; 7: 1793-804.
16. Kirchheimer JC, Christ G, Binder BR. Growth stimulation of human epidermal cells by urokinase is restricted to the intact active enzyme. Eur J Biochem 1989; 181: 103-7.
17. Kristensen P, Larsson L-I, Nielsen LS. Grøndahl-Hansen J, Andreasen PA, Danø K. Human endothelial cells contain one type of plasminogen activator. FEBS Lett 1984; 168: 33-7.
18. Lotti T, Benci M. Plasminogen activators, venous leg ulcers and reepithelialization. Int J Dermatol 1995; 34: 696-9.
19. Lotti T, Fabbri P, Panconesi E. The pathogenesis of venous ulcers. J Am Acad Dermatol 1987; 16: 877-9.
20. Palolahti M, Lauharanta J, Stephens RW, Kuusela P, Vaheri A. Proteolytic activity in leg ulcer exudate. Exp Dermatol 1993; 2: 29-37.
21. Rogers AA, Burnett S, Moore JC, Shakespeare PG, Chen WYJ. Involvement of proteolytic enzymes - plasminogen activators and matrix metalloproteinases - in the pathophysiology of pressure ulcers. Wound Rep Regen 1995; 3: 273-83.
22. Rømer J, Lund LR, Eriksen J, Ralfkiær E, Zeheb R, Gelehrter TD, Danø K, Kristensen P. Differential expression of urokinase-type plasminogen activator and its type-1 inhibitor during healing of mouse skin wounds. J Invest Dermatol 1991; 97: 803-11.
23. Sappino A-P, Huarte J, Vassalli J-D, Belin D. Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney. J Clin Invest 1991; 87: 962-70.
24. Schäfer BM, Maier K, Eickhoff U, Todd RF, Kramer MD. Plasminogen activation in healing human wounds. Am J Pathol 1994; 144: 1269-80.
25. Scott HJ, Coleridge Smith PD, Scurr JH. Histological study of white blood cells and their association with lipodermatosclerosis and venous ulceration. Br J Surg 1991; 78: 210-1.
26. Sordat BCM, Tran-Thang C. Laminin degradation by human colon carcinoma cells: a role for urinary and tissue plasminogen activators. Invasion Metastasis 1994/95; 14: 223-33.
27. Shami SK, Sarin S, Scurr JH. Chronic venous insufficiency disease. Int J Angiol 1997; 6: 30-48.
28. Spiers EM, Lazarus GS, Lyons-Giordano B. Expression of plasminogen activator enzymes in psoriatic epidermis. J Invest Dermatol 1994; 102: 333-8.
29. Stacey M, Burnand KG, Mahmoud-Alexandroni M, Gaffney PJ, Bhogal BS. Tissue and urokinase plasminogen activators in the environs of venous and ischaemic leg ulcers. Br J Surg 1993; 80: 596-9.
30. Todd AS. Endothelium and fibrinolysis. Atherosclerosis 1972; 15: 137-40.
31. Vassalli J-D, Belin D. Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett 1987; 214: 187-91.
32. Vassalli JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991; 88: 1067-72.
33. Wilkinson LS, Bunker C, Edwards JCW, Scurr JH, Coleridge Smith PD. Leukocytes: their role in the etiopathogenesis of skin damage in venous disease. J Vasc Surg 1993; 17: 669-75.
34. Wysocki AB, Staiano-Coico L, Grinnell F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest Dermatol 1993; 101: 64-8.
35. Yager DR, Chen SM, Ward SI, Olutoye OO, Diegelmann RF, Cohen IK. Ability of chronic wound fluids to degrade peptide growth factors is associated with increased levels of elastase activity and diminished levels of proteinase inhibitors. Wound Rep Regen 1997; 5: 23-32.
36. Yager DR, Zhang L-Y, Liang H-X. Diegelmann RF, Cohen IK. Wound fluids from human pressure ulcers contain elevated matrix metalloproteinase levels and activity compared to surgical wound fluids. J Invest Dermatol 1996; 107: 743-8.